GUSTAVO ALVA: Open Payments
NPI 1417030222 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,138,182 in 1,015 payments from 30 companies in 2025. Trend: 2023 $1,066,079 · 2024 $1,052,848 · 2025 $1,138,182
Speaker / faculty: $676,676Travel & lodging: $161,079Honoraria: $139,594Consulting: $129,973Food & beverage: $25,630Speaker / faculty: $5,225
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 144 | $178,998 |
| E.R. Squibb & Sons, L.L.C. | 127 | $173,475 |
| Axsome Therapeutics, Inc. | 112 | $160,403 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 133 | $134,051 |
| Vanda Pharmaceuticals Inc. | 101 | $125,595 |
| Otsuka America Pharmaceutical, Inc. | 55 | $69,012 |
| Janssen Pharmaceuticals, Inc | 54 | $60,168 |
| ABBVIE INC. | 75 | $56,123 |
| Neurocrine BioSciences, Inc. | 61 | $48,004 |
| Alkermes, Inc. | 45 | $46,513 |
Products named: Auvelity, COBENFY, CAPLYTA, FANAPT, AUSTEDO XR, REXULTI, INVEGA SUSTENNA, VRAYLAR.
Industry payments across CA — which companies pay providers there.
